Pauza Charles David 4

4 · Traws Pharma, Inc. · Filed Apr 3, 2024

Form 4

Period: 2024-04-01

Chief Science Officer Virology

Transactions

Award
Common Stock
2024-04-01+97,500→ 97,500 total
Award
Stock Option (right to purchase)
2024-04-01+333,136→ 333,136 total
Exercise: $0.07From: 2023-11-01Exp: 2033-10-31→ Common Stock (333,136 underlying)
Award
Stock Option (right to purchase)
2024-04-01+503,227→ 503,227 total
Exercise: $0.01From: 2023-11-01Exp: 2033-10-31→ Common Stock (503,227 underlying)

Footnotes (4)

[F1]Represents an award of restricted stock units that will vest in four equal annual installments beginning April 1, 2025. Each restricted stock unit will convert into shares of common stock of Traws Pharma, Inc. (f/k/a Onconova Therapeutics, Inc., the "Company"), par value $0.01 per share ("Common Stock"), on a one-for-one basis.
[F2]On April 1, 2024, the Company acquired Trawsfynydd Therapeutics, Inc. ("Trawsfynydd") in accordance with the terms of an Agreement and Plan of Merger, dated April 1, 2024 (the "Merger Agreement"), by and among the Company, Traws Merger Sub I, Inc., Traws Merger Sub II, LLC, and Trawsfynydd (the "Merger"). Upon consummation of the Merger, all of the outstanding shares of common stock of Trawsfynydd were converted into shares of Common Stock on a 1:20.1291 basis pursuant to the terms of the Merger Agreement.
[F3]Received in the Merger in exchange for stock options to acquire 16,550 shares of Trawsfynydd common stock with an exercise price of $1.38 per share.
[F4]Received in the Merger in exchange for stock options to acquire 25,000 shares of Trawsfynydd common stock with an exercise price of $0.0001 per share.

Documents

1 file